Abstract: The present invention relates to a reversible fluorescence photoswitch based on the dye-crosslinked dendritic nanoclusters for high-contrast imaging of living biological systems. The dendritic nanocluster according to the present invention consists of two or more dendrimers crosslinked each other to have a globular shape overall, and thereby enhancing the fluorescence intensity and improving the detection sensitivity of the monomeric dendrimers. In addition, the dendritic nanocluster according to the present invention was found to internalize into a living zebrafish by both skin permeation and microinjection, independently. Further, the dendritic nanocluster according to the present invention showed low toxicity and thus it could be useful for both in vivo and in vitro imaging as well as the ex vivo cell tracking applications.

Abstract: The present invention provides a medical device for placement into a lumen such as a stent and a catheter whose surface is uniformly and sufficiently coated with a drug, and a process thereof with easy way and with low cost. The medical device is coated with mixed particles of drug particles whose surface is modified with positive-charge and biocompatible nanoparticles. In the invention, a drug can be taken into a cell through the dissolution of the drug particle together with the biocompatible nanoparticle after a DES is placed in a biological body.

Abstract: This invention is directed to a pharmaceutical composition for drinking water administration comprising benzimidazole carbamate particles having an effective average particle size of less than 450 mm and a Tween-type surfactant; a method for making the composition; use of the composition to make a medicament for controlling parasites; and use of said composition for the manufacture of a medicament or protecting animal from parasitic infection.

Abstract: Described herein are methods for treating a subject with combinations of polymer-agent particles and cyclodextrin polymer agent conjugates. The methods herein may be used to treat subjects identified with cancer, cardiovascular disorders, autoimmune disorders, or inflammatory disorders. Also described herein are compositions, dosage forms, and kits comprising polymer-agent particles and cyclodextrin polymer agent conjugates.

Abstract: Degradable polymeric compositions containing water-insoluble drugs blended with copolymers of biocompatible diphenol compound monomer units with pendant carboxylic acid groups polymerized with biocompatible diphenol compound monomer units with pendant carboxylic acid ester groups and poly(alkylene oxide) blocks, wherein the molar fraction in the copolymer of biocompatible diphenol compound monomer units with pendant carboxylic acid groups and poly(alkylene oxide) blocks relative to the weight percentage of the drug in the composition is effective to provide pseudo-zero order release of the drug from the composition during the sustained-release phase of drug delivery under physiological conditions. Ocular treatment methods and manufacturing methods are also disclosed.

Abstract: A structured liquid detergent composition in the form of a liquid matrix made up of an external structuring system of a bacterial cellulose network; water; and surfactant system including an anionic surfactant; a nonionic surfactant; a cationic surfactant; an ampholytic surfactant; a zwitterionic surfactant; or mixtures thereof, wherein said liquid matrix has a yield stress of from about 0.003 Pa to about 5.0 Pa at about 25° C. and provides suitable particle suspension capabilities and shear thinning characteristics.

Abstract: The present invention provides a method and product for transdermal delivery of therapeutics, including neurotoxins and methods for use thereof. The method and system comprises pharmaceutical compositions for facilitating transdermal delivery of therapeutics without pain by absorption and more particularly a series of pharmaceutical formulations for topical administration of neurotoxins to humans, including a neurotoxin, such as a botulinum toxin, and absorption enhancing agents that facilitate absorption of the neurotoxin through the skin of the patient and do not eliminate the bioactivity associated with the neurotoxin. The pharmaceutical compositions are topically applied on a patient, and are generally in a cream or gel form.

Abstract: An antimicrobial composite structure including: a polymeric material, the material having a first exterior surface expanded to fibrils and nodes, a second exterior surface and an interior portion between the exterior surfaces; and nanoparticles present in the interior portion adjacent the first exterior surface but not in the interior portion adjacent the second exterior surface. The nanoparticles can be silver nanoparticles and the polymeric material may be an expanded fluoropolymer material such as expanded polytetrafluoroethylene.

Abstract: The present invention relates to a process for the preparation of colloidal systems, such as nanocapsules and nanoparticles, which incorporates a homogenization step for reducing particle size.

Abstract: The present invention relates to pharmaceutical compositions for the controlled release of lipocalin muteins and conjugates thereof with a moiety selected from the group consisting of a protein, protein domain, peptide, lipid, fatty acid, polysaccharide and/or an organic polymer that comprise said lipocalin mutein of conjugate thereof in combination with a biodegradable polymer. The invention further relates to a method for the controlled delivery of the lipocalin muteins or conjugates thereof, methods for the production of a controlled release formulation and the thus produced formulation.

Abstract: This invention relates to the long term treatment of HIV infection by intermittently administering a parenteral formulation comprising brecanavir at relatively long time intervals. This invention further concerns pharmaceutical compositions for parenteral administration, comprising micro- or nanoparticles of brecanavir, suspended in an aqueous pharmaceutically acceptable carrier, for the treatment and prophylaxis of HIV infection.

Abstract: A method for determining the presence of a compound in a liquid solution, by admixing the liquid solution with a plurality of nanoparticles; providing conditions effective to cause aggregation of the nanoparticles in the liquid solution in the absence of said compound in the liquid solution; and observing a detectable signal reflecting the amount of aggregation of nanoparticles in the liquid solution, wherein the presence of the compound in the liquid solution results in a detectable signal reflecting a reduced amount of aggregation of nanoparticles in the liquid solution, in comparison to the amount of aggregation of nanoparticles obtained in the liquid solution in the absence of the compound therein. A nanoparticle, a composition, a kit and a for multi-well plate for use in the method are also disclosed. In some embodiments the association is cation-, anion and/or PH induced e.g. by using helix-loop-helix polypeptides as first and second molecules attached to the nanoparticles.

Abstract: In various embodiments, the present disclosure describes processes for preparing functionalized graphene nanoribbons from carbon nanotubes. In general, the processes include exposing a plurality of carbon nanotubes to an alkali metal source in the absence of a solvent and thereafter adding an electrophile to form functionalized graphene nanoribbons. Exposing the carbon nanotubes to an alkali metal source in the absence of a solvent, generally while being heated, results in opening of the carbon nanotubes substantially parallel to their longitudinal axis, which may occur in a spiralwise manner in an embodiment. The graphene nanoribbons of the present disclosure are functionalized on at least their edges and are substantially defect free. As a result, the functionalized graphene nanoribbons described herein display a very high electrical conductivity that is comparable to that of mechanically exfoliated graphene.

Abstract: Compositions comprising one or more rifamycin antibiotics and one or more bile acids, and methods of using the compositions for the treatment of infection.

Abstract: Described are conjugated polymer fibers and nanofibers, methods of making, and methods of use thereof. The conjugated polymer fibers and nanofibers can be prepared by an electrostatic spinning process followed by crosslinking.

Abstract: A keyboard includes a first substrate, a second substrate, a first electrode layer, and a second electrode layer. The first substrate includes a first upper surface and a first lower surface opposite the first upper surface. The second substrate is positioned apart from the first substrate and includes a second upper surface and a second lower surface. The second upper surface faces the first lower surface. The first electrode layer is positioned on the first lower surface and includes a number of first conductive layers disposed apart from each other and including a carbon nanotube layer structure. The second electrode layer is positioned on the second upper surface and includes a second conductive layer. A number of keys is positioned on the first upper surface or the second lower surface.

Abstract: Preconcentrates comprising a fatty acid oil mixture and at least one surfactant, and methods and uses thereof are disclosed. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system (SNEDDS), a self-microemulsifying drug delivery system (SMEDDS), or self-emulsifying drug delivery systems (SEDDS) in an aqueous solution.

Abstract: Systems and methods are provided for filtering a fluid containing nanoparticles. The systems and methods generally include introducing a stream of the nanoparticle-containing fluid into a holding vessel, and extracting at least a part of a nanoparticle-containing fluid accumulated in the holding vessel. The extracted nanoparticle-containing fluid is passed through a filtration module to separate a nanoparticle-containing retentate from a permeate, and the retentate is returned to the vessel. The filtration cycle can be repeated until a desired concentration of the nanoparticles is achieved in the holding vessel. In many embodiments, the generation of the nanoparticle-containing fluid and its filtration are performed concurrently.

Abstract: Reactive system comprising at least one component (I) composed of particles in very finely divided form present in a liquid phase of at least one further component (II) with which component (I) is capable of reacting following activation through energy supply, wherein component (I) is not soluble in component (II), process for preparation and use.

Abstract: The invention is directed to biocompatible conjugated polymer nanoparticles including a copolymer backbone, a plurality of sidechains covalently linked to said backbone, and a plurality of platinum compounds dissociably linked to said backbone. The invention is also directed to dicarbonyl-lipid compounds wherein a platinum compound is dissociably linked to the dicarbonyl compound. The invention is also directed to methods of treating cancer or metastasis. The methods includes selecting a subject in need of treatment for cancer or metastasis and administering to the subject an effective amount of any of the nanoparticles, compounds, or compositions of the invention.

Abstract: The present invention relates to a lipid nanoparticle system comprising a lipid component, a cationic surfactant, a non-ionic surfactant, a polysaccharide and, optionally, a positively charged peptide, useful for the release of pharmacologically active molecules, and especially for transfecting genetic material into cells and/or tissues. It also relates to methods for obtaining nanoparticles, to pharmaceutical compositions comprising it, as well as to the use thereof in gene therapy.

Abstract: The present application relates to Nanoparticle bioengineering techniques were used to produce a non-toxic polypyrrole composition having two-dimensional and three-dimensional structures that can optionally be co-polymerized with carboxylic acid moieties to possess hydrophilicity. Likewise, such polypyrrole/carboxylic acid structures may be further modified with neural growth factors to create treatment surfaces that can promote growth an differentiation of cells such as neurons.

Abstract: Non-Small Cell Lung Carcinomas (NSCLCs) are treated with Gel Micro-Particles (GMPs) that passively accumulate in the lungs and contain Nano-Particles (NPs) combining one or more therapeutic agents that are cytotoxic to the NSCLC with one or more NSCLC active targeting ligands, as well as one or more other optional agents that increase cellular uptake, enhance the pro-apoptotic effect of the chemotherapeutic agent(s), and the like. NPs targeting other cancer cells are also disclosed, as well as NP-containing GMPs that reduce the occurrence of tumor metastasis.

Abstract: A compound containing at least two pyridinium derivatives in its molecular structure and being in a reduced form thereof may be used as a CNT n-doping material. The compound may donate electrons spontaneously to CNTs to n-dope the CNTs, while being oxidized into its stable state. An n-doped CNT that is doped with the CNT n-doping material may maintain a stable n-doped state for a long time without being dedoped even in the air and/or water. Further, the n-doped state may be easily controlled when using the CNT n-doping material.

Abstract: The present invention relates to a nanoparticle of oxaliplatin, which is a water-soluble active substance, a pharmaceutical composition containing the same, and a method for preparing an orally administrable oxaliplatin nanoparticle by emulsifying a lipid mixture solution wherein a solid lipid and a surfactant are mixed in an aqueous mixture solution wherein oxaliplatin and a specific cosolvent are mixed and then removing the solid lipid and the cosolvent using a supercritical fluid gas. By providing oxaliplatin, which is currently available only in injection form for parenteral administration, in the form of a nanoparticle, the present invention allows for the development of orally administrable oxaliplatin which is stable against gastric acid and has improved bioavailability, thereby improving patient compliance through avoiding the inconvenience of injection and greatly reducing medical cost.

Abstract: Topical composition for use especially as a skin lightener, characterized in that it contains an effective amount of at least one compound of general formula (I) or a mixture of such compounds and/or an acid addition salt thereof: in which X is NH or a direct bond and n is 2, 3 or 4, preferably 2 or 3, and its use for lightening skin colour, for depigmenting liver spots and for evening out non-uniformities in skin colouration. The invention further relates to dermatologically effective compositions containing at least one disulfide of general formula (I) and at least one additional skin care ingredient.

Abstract: The present invention is directed to delivery complexes of rosette nanotubes and one or more biologically active agents or diagnostic agents.

Abstract: A metal cyanide complex catalyst and its preparation and application are disclosed. The formula of this catalyst is M1a[M2(CN)bL1c]d(X)m(L2)n·xSu·yL3·zH2O and its preparation method comprises: (A) adjusting pH of a mixed solution I? of L3, M3e[M2(CN)bL1c]f, de-ionized water I, alcohol and/or ether solvent to less than 7.0, and adding it into a mixed solution II? of M1(X)g salt, Su or Su precursor, de-ionized water II, stirring for reaction under 20° C.-120° C. for 0.5-200 hours, separating and drying to obtain a solid product; and (B) repeatedly dispersing the solid into an anhydrous organic solvent containing L2 to form a slurry, distilling, separating and drying to obtain the metal cyanide complex catalyst. The catalyst is useful in preparing polyethers, polycarbonates and polyesters by homopolymerization of epoxides, or copolymerization of epoxides with carbon dioxide or anhydrides.

Abstract: A substrate assembly containing a conductive film and a fabrication method thereof are provided. The substrate assembly includes a polymer substrate, a surface treatment layer formed on the polymer substrate and a conductive film formed on the surface treatment layer, wherein the conductive film is formed by sintering a metal conductive ink and the surface treatment layer is formed from a composite material of an auxiliary filler and a polymer. The auxiliary filler in the surface treatment layer can deliver energy into the metal conductive ink for sintering the conductive metal ink.

Abstract: A method for treating cancer, preventing cancer or delaying the progression of a cancer in an animal or human comprising the step of: administering to the animal or the human having a cancer a composition in an amount effective to treat cancer, prevent cancer or delay the progression of cancer in the animal or the human. The composition comprises a pharmaceutically acceptable excipient, and ascorbate which is joined to a carrier structure containing an anti-cancer active agent, said carrier structure being capable of releasing the anti-cancer agent in the presence of a reactive oxygen species.

Abstract: An artificial oxygen carrier (AOC) for use in the body. A first gas permeable first shell encloses an oxygen carrying agent. The first shell has a second oxygen carrying agent surrounding it, and there is a second gas permeable shell enclosing the second agent. The concentric shells are not subject to turbulent breakup, or chemical decomposition, do not release the agents.

Abstract: The present invention relates to a method for preparing nanoparticles at least partially consisting of rare earth fluoride, characterized in that said fluoride is produced, in a solution, from a salt of the corresponding rare earth element and from a charge-transfer complex of formula (I), where Ra, Rb, and Rc are as defined in claim 1.

Abstract: Shampoo compositions comprise (a) from about 5% to about 50% of one or more detersive surfactants; (b) a dispersed gel network phase comprising: (i) at least about 0.05% of one or more fatty amphiphiles; (ii) at least about 0.01% of one or more secondary surfactants; and (iii) water; (c) at least about 0.05% of a galactomannan polymer derivative with a net positive charge and having a mannose to galactose ratio of greater than 2:1 on a monomer to monomer basis, wherein the galactomannan polymer derivative has: (i) a molecular weight from about 1,000 to about 10,000,000; and (ii) a cationic charge density from about 0.7 meq/g to about 7 meq/g; and (d) at least about 20% of an aqueous carrier; all by weight of the shampoo composition.

Abstract: The present invention provides an organic dispersion of inorganic platelets, which includes an organic solvent and H-form inorganic platelets dispersed therein. The H-form inorganic platelets have a particle size of between about 20 and 80 mm and the organic dispersion has a sold content of between about 1 and 20 wt %. A method for forming the organic dispersion is also provided.

Abstract: Porous three-dimensional networks of polyurea and porous three-dimensional networks of carbon and methods of their manufacture are described. In an example, polyurea aerogels are prepared by mixing an triisocyanate with water and a triethylamine to form a sol-gel material and supercritically drying the sol-gel material to form the polyurea aerogel. Subjecting the polyurea aerogel to a step of pyrolysis may result in a three dimensional network having a carbon skeleton, yielding a carbon aerogel. The density and morphology of polyurea aerogels can be controlled by varying the amount of isocyanate monomer in the initial reaction mixture. A lower density in the aerogel gives rise to a fibrous morphology, whereas a greater density in the aerogel results in a particulate morphology. Polyurea aerogels described herein may also exhibit a reduced flammability.

Abstract: The invention relates to a process for the preparation of polyamide nanofibers by electrospinning, wherein the process is a multi-nozzle electrospinning process with the use of a multi-nozzle device or a nozzle-free electrospinning with the use of nozzle free device, comprising steps wherein a high voltage is applied, a polymer solution comprising a polymer and a solvent is fed to the multi-nozzle device or the nozzle free device and transformed under the influence of the high voltage into charged jet streams the jet streams are deposited on a substrate or taken up by a collector, and the polymer in the jet streams solidifies thereby forming nanofibres, and wherein the polymer comprises a semi-crystalline polyamide having a C/N ratio of at most 5.5 and a weight average molecular weight (Mw) of at most 35,000. The invention also relates polyamide nanofibers made by the electrospinning process, as well as to products made thereof and use thereof.

Abstract: The present invention is directed to the preparation and use of aromatic polyimide nanowebs with amide-modified surfaces. Uses include as a filtration medium, and as a separator in batteries, particularly lithium-ion batteries. The invention is also directed to a filtration apparatus comprising the aromatic polyimide nanoweb with amide-modified surface. The invention is further directed to a multi-layer article comprising the aromatic polyimide nanoweb with amide-modified surface, and to an electrochemical cell comprising the multi-layer article.

Abstract: The present teachings provide a fuser member. The fuser member includes a substrate layer comprising a polyamideimide/polybenzimidazole polymer blend. A method of manufacturing the fuser member is described.

Abstract: The invention discloses novel morphology shifting micelles and amphiphilic coated metal nanofibers. Methods of using and making the same are also disclosed.

Abstract: The present teachings provide a fuser member. The fuser member includes a substrate layer comprising a polyimide polymer and polyethylene glycol ester.

Abstract: Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include small particles of a poorly soluble therapeutic agent that facilitates formation of concentrated regions of the therapeutic agent in the retinal pigmented epithelium of an eye. The particles are formed by combining a therapeutic agent with an ophthalmically acceptable polymer component. The particles have sizes less than about 3000 nanometers, and in some cases, less than about 200 nanometers. One example of composition includes particles of triamcinolone acetonide and hyaluronic acid have a size less than about 3000 nanometers.

Abstract: Method for treating thermoplastic to make a surface thereof superhydrophobic. The method includes exposing the thermoplastic to a specific solvent for a selected time period. It is preferred that the treatment time be in the range of one minute to approximately five hours and more preferably in the range of one minute to 15 minutes. Thermoplastics and solvents having a similar solubility parameter interact with one another to form hydrophobic hierarchical surfaces.

Abstract: The invention relates to a nanofibre membrane layer having a basis weight of 0.01-50 g/m2 and a porosity of 60-95%, comprising a nanoweb made of polymeric nanofibres with a number average diameter in the range of 50-600 nm, consisting of a polymer composition comprising a semicrystalline polyamide having a C/N ratio of at most 5.5. The invention also relates to water and air filtration devices comprising such a nanofibre membrane layer.

Abstract: Fluids comprising graphite particles and related methods are generally described. In some embodiments, “microfluids” are described. Generally, the microfluids can comprise a fluid and a plurality of graphite particles with microscale dimensions.

Abstract: Cationic poly(ester ether amide)s (PEEAs) and compositions comprising PEEAs and biomolecules such as nucleic acids and proteins. Also, a method for intracellular delivery of biomolecules using complexes of the PEEAs and biomolecules. For example, PEEAs can be used as transfection agents for nucleic acids such as DNA and RNA.

Abstract: Stable solutions of lipophilic drugs, such as cyclosporin, forming a polar lipid self-emulsifying drug delivery system. The solutions can include lipophilic drugs, such as cyclosporin, dissolved in a polar lipid, such as having a C6-C12 fatty acid monoglyceride content of at least about 50%, surfactants and triglycerides. The composition forms a fine emulsion on exposure to water. The encapsulated dosage form of this composition needs neither a hydrophilic component nor air-tight blister packaging, and is particularly suitable for oral administration.

Abstract: The invention relates to composite blend membranes formed from blends of one or more polyelectrolytes, and one or more types of nanoparticles. Preferably the blend also includes one or more fluoropolymers. The addition of the nanoparticles was found to enhance the conductivity and mechanical properties of the membranes.

Abstract: The present invention relates to methods for producing particles of indomethacin using dry milling processes as well as compositions comprising indomethacin, medicaments produced using indomethacin in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of indomethacin administered by way of said medicaments.

Abstract: The present invention provides methods and devices for the fabrication of 3D polymeric fibers having micron, sub-micron, and nanometer dimensions, as well as methods of use of these polymeric fibers.

Abstract: The present invention is directed to nanostructured (nanoparticulated) Telmisartan compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Telmisartan according to the invention have an average particle size of less than about 600 nm. Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension.